Novel anti-HER2 agents for HER2-low BC, such as trastuzumab deruxtecan (TDXd; Enhertu, Daiichi Sankyo, Inc.), could improve prognosis for some patients currently excluded from HER2-targeted therapy, thereby expanding the reach to a much larger share of BC patients [7]. The gene discussed is ERBB2; the disease is breast cancer.